Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 北京天智航医疗科技股份有限公司(股票代码:688277;以下简称“天智航”)是一家专注从事骨科手术机器人及其相关技术自主创新、规模化生产、专业化营销及优质临床应用为一体的高新技术企业,也是国内第一家、全球第五家获得医疗机器人注册许可证的企业。2020年,天智航公司成功上市IPO科创板。 天智航作为中国医疗机器人开拓者,获得了200余项专利,是“国家机器人标准化总体组”成员单位,“医疗机器人国家地方联合工程研究中心”依托单位,“北京市医疗机器人产业创新中心”依托单位;是中国医学装备协会理事单位,中国生物医学工程学会医用机器人工程与临床应用分会副主任委员单位,中关村医疗器械产业技术创新联盟理事长单位,中国机器人TOP10峰会的成员企业,北京市生物医药产业跨越发展工程(G20工程)创新引领企业,曾获2015年国家科学技术进步奖二等奖等国家级和省部级的多项荣誉,拥有博士后科研工作站。 天智航核心产品——天玑骨科手术机器人——用于辅助医生精确定位植入物或手术器械,可广泛应用于脊柱和创伤骨科手术,其临床精度可达1mm以内,可显著减少术中辐射并提高手术效率,使复杂手术简单化、常规手术标准化、开放手术微创化、医疗资源均等化,助力医生成功,造福患者,服务“健康中国”战略,助力我国实现高端医疗装备自主可控,智慧骨科的未来可期。截止2023年第一季度末,天玑系列骨科机器人的临床应用已覆盖170余家医疗机构,30个省、自治区、直辖市,手术量突破40000例。 | ||||||||||||||||||||||||
Main Business | 骨科手术导航定位机器人的研发、生产、销售和服务 | ||||||||||||||||||||||||
Legal Representative | 张送根 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 黄军辉 | ||||||||||||||||||||||||
Solicitors | 北京德恒律师事务所 | ||||||||||||||||||||||||
Auditors | 上会会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 010-82156660-8009 | ||||||||||||||||||||||||
Fax No | 010-82947808 | ||||||||||||||||||||||||
Website | www.tinavi.com | ||||||||||||||||||||||||
tinavi@tinavi.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 07/07/2020 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.350 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 2.754 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 4.782B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |